Stress Urinary Incontinence - Opinion Divided on Drug Therapy

Questions: Discounts, Updates etc.

Price: $15,200.00

Publication Date: 2006-04-14

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Stress urinary incontinence (SUI) is the most common type of urinary incontinence in women. Up until recently there were no globally developed or widely approved pharmacological treatments for this disorder leaving women with few treatment optionsnon-invasive (e.g. pelvic floor exercises) or invasive (i.e. surgery) non-pharmacological therapy.


Scope

  • Quantitative treatment data from 419 physicians based in US, Japan, France, Germany, Italy, Spain and the UK; supported by key opinion leader comments
  • Analysis of epidemiology, presentation and referral patterns, diagnostic assessment, and first- to third-line pharmacological treatments for SUI
  • Influences on treatment choice and perception of current drug therapies including duloxetine
  • Evaluation of unmet needs and future outlook including awareness of R&D drug pipeline


    • Report Highlights
    Despite the high prevalence of SUI among women, a number of factors including embarrassment and poor awareness amongst women act as a barrier to sufferers seeking help for their condition. There is a need for better education and treatment options to improve diagnosis and treatment rates.

    Without the widespread availability of an efficacious drug for SUI, many physicians have become reliant on non-pharmacological techniques. Patients and primary care physicians, with little experience of surgery, are less likely to be confident with this treatment option and it is here that pharmacological treatments could gain more support.

    The approval of Yentreve (duloxetine) for SUI in the EU has provided another treatment option. However, uptake has not been as rapid as Lilly would have hoped and although this may have been influenced by satisfaction with surgical treatment, to date the available clinical data and experience in clinical practice, has not always been positive.


    Reasons to Purchase

  • Forecast product sales by understanding key aspects of SUI epidemiology, diagnosis and treatment
  • Gain a better understanding of the challenges facing current and future players in the SUI market
  • Identify physicians key concerns in SUI including unmet needs and the attributes that physicians believe are desirable for future treatments

    • Table of Contents

    Other users found this report page using the following search terms: incontinence overactive bladder urge incontinence stress incontinence incontinence stress urinary ppt drug treatment therapy incontinenceppt powerpoint non

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.


    Refund and Cancellation Policy: The descriptions of the products and services sold on LeadDiscovery.co.uk are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.